Makers of some of the most lucrative pharmaceutical products ever produced are headed for a slump in revenues as deliveries of Covid-19 vaccines almost halve next year, according to new forecasts.
根据最新预测，由于明年新冠疫苗的交付量几乎减半，有史以来最赚钱的一些医药产品制造商将面临收入下滑的局面。
您已阅读5%（248字），剩余95%（4565字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。